The lower frequency of these two variants in dPMS2 tumours, combined with the fact that KRAS variants are known to occur in a relatively late stage of tumour progression, has led to the hypothesis that loss of the wildtype PMS2 allele is a secondary and not an initiating event in CRCs that develop in path_PMS2 carriers. This evidence concerns the gene PMS2 and neoplasm.